CellFE Announces Addition of Life Science Tools Veteran Mike Rice to Board of Directors
CellFE Announces Addition of Life Science Tools Veteran Mike Rice to Board of Directors
Non-Viral Cell Therapy Manufacturing System Enables Faster Development Time and Healthier Cells vs. Electroporation
非病毒細胞治療製造系統可以比電穿孔更快地開發時間和更健康的細胞。
ALAMEDA, Calif., June 25, 2024 /PRNewswire/ -- CellFE Inc., a cell engineering platform company with a novel microfluidic technology for non-viral cell therapy manufacturing, announced today that life science tools executive Mike Rice has been appointed to its Board of Directors. Mr. Rice previously served as Chairman & CEO at BioLife Solutions, a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets.
加利福尼亞州阿拉米達，2024年6月25日/美通社—擁有新型微流控技術的細胞工程平台公司CellFE Inc.宣佈，生命科學工具行業領導人Mike Rice已被任命爲公司董事會成員。Rice先生曾擔任BioLife Solutions的董事長兼首席執行官，BioLife Solutions是細胞和基因治療（CGT）及更廣泛生物製藥市場的主要生產工具和服務供應商。
Board member Christian Uhrich, Investment Director at M Ventures, remarked, "We are thrilled that Mike has joined the CellFE Board as his experience in successfully scaling up a life sciences tool business will be invaluable to the team. We look forward to Mike's contributions during this exciting inflection point for our portfolio company."
董事Christian Uhrich是M Ventures的投資總監，他評論道：“我們非常高興Mike加入CellFE董事會，因爲他成功擴大生命科學工具業務的經驗將對團隊非常有價值。在我們的投資組合公司迎來這個激動人心的拐點時期，我們期待Mike的貢獻。”
Alla Zamarayeva, CellFE co-founder and CEO, commented, "CellFE's cell engineering platform is increasingly being recognized for its unique non-viral approach to manufacture cell therapies. This recognition is validated as our customers continue to generate compelling performance data. The CellFE team is poised to disrupt cell therapy manufacturing, and we look forward to working with Mike. His industry expertise will be invaluable as we accelerate our commercial outreach and amplify CellFE's brand awareness and value proposition to pharmaceutical and biotech sectors."
CellFE聯合創始人兼首席執行官Alla Zamarayeva評論道：“越來越多的人認識到CellFE的細胞工程平台具有獨特的非病毒製造細胞治療的方法，這得到了驗證，因爲我們的客戶繼續生成令人信服的性能數據。CellFE團隊的目標是顛覆細胞治療製造領域，我們期待與Mike合作。隨着我們加快商業推廣並提高CellFE的品牌知名度和對藥品和生物技術行業的價值主張，他的行業專業知識將非常有價值。”
Rice offered, "Alla and Todd have built a great team and I'm impressed with the entire leadership group and the progress the company has made in gaining market traction with the Infinity MTx Cellular Engineering Platform. This is a critical time for the CGT space, as developers seek to reduce manufacturing costs and processing time, while increasing therapeutic potency. The CellFE system has the potential to disrupt the space and become a new standard."
Rice表示：“Alla和Todd已經建立了一個優秀的團隊，我對整個領導團隊和公司在推進Infinity MTx細胞工程平台市場吸引力方面所做的進展印象深刻。這是CGT領域的關鍵時刻，開發者試圖降低製造成本和加工時間，同時增加治療效力。CellFE系統有可能顛覆這個領域，成爲一個新的標準。”
About CellFE, Inc.
關於CellFE, Inc. CellFE是一家尖端微流控公司，正在改變開發和製造拯救生命的細胞治療方案，使患者更容易獲得。公司的基於微流控的細胞工程平台提供了降低易位事件風險的複雜編輯、簡化的可擴展性和快速的工作流程。CellFE平台的優點包括使細胞的健康和產量更爲優越，同時縮短了擴大時間，大大減少了靜脈到靜脈時間，並且使治療更加強大耐用。通過限制對專業緩衝液的需求，該技術確保了優化可從低到高的容量直接轉移，因此細胞治療開發者可以無縫地從研究到臨床和更高階段進行規模化。CellFE致力於通過緊密合作來解決開發和製造下一代細胞治療方案所面臨的挑戰，以實現他們的合作伙伴的成功。有關更多信息，請訪問。
CellFE, a cutting-edge microfluidics company, is transforming the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. The Company's microfluidic-based cell engineering platform offers complex editing with reduced risk of translocation events, streamlined scalability, and rapid workflows. Benefits of the CellFE platform include superior cell health and yield with reduced expansion times, drastically minimizing both vein-to-vein times and enabling more robust and durable therapies. By limiting the need for specialized buffers, the technology ensures optimization is directly transferrable from low to high volumes, so cell therapy developers can seamlessly scale from research to clinical and beyond. CellFE is committed to enabling their partners' success through close collaborations designed to solve the challenges associated with the development and manufacturing of next-generation cell therapies. For more information, please visit .
電芯FE是一家領先的微流控公司，正在改變生命救助細胞治療的開發和製造，使其更加易於患者接受。該公司的微流控細胞工程平台提供複雜的編輯功能，並降低了搬移事件的風險，具有流程可擴展性和快速工作流程的優勢。電芯FE平台的優點包括在減少擴增時間的同時提高細胞健康和產量，大大減少了靜脈-靜脈時間，從而實現了更強大、更持久的治療方法。 通過限制對特殊緩衝液的需求，該技術確保優化可直接從低到高體積轉移，因此細胞治療開發人員可以輕鬆地從研究到臨床等方面進行無縫縮放。電芯FE致力於通過緊密合作解決下一代細胞治療開發和製造所面臨的挑戰。更多信息請訪問。
SOURCE CellFE
消息來源：電芯FE
譯文內容由第三人軟體翻譯。